Literature DB >> 32395551

Heterotopic accessory spleen with squamous epithelial cyst in pancreas mimicking other pancreatic tumor: a case report.

Jieli Luo1, Jianshe Chen1, Fengbo Huang2, Panpan Zhou3, Pintong Huang1.   

Abstract

A 49-year-old female undergoing a periodic health examination at other hospital revealed a mass in the tail of pancreas. The patient denied any personal history of surgery except subtotal hysterectomy because of multiple myomas in uterus 7 years ago, family history of abdominal cancer and trauma. Physical examination and laboratory finding (including tumor marker) were unremarkable. Chest X-ray result was normal. Contrast enhanced ultrasound (CEUS) examination showed a well-defined hypoechoic pancreatic mass which was suggestive of solid pseudopapillary tumor. Contrast enhanced computed tomography (CE-CT) of the abdomen revealed a mass of hypodensity suggestive of intraductal papillary mucinous neoplasm. Because of the risk of bleeding and exclusion of surgical contraindications, patient underwent laparoscopic surgery. Intraoperatively, a solid mass was identified in the tail of pancreas, the intraoperative frozen pathological examination suggested a heterotopic accessary spleen (HAS) with squamous epithelial cyst. Partial pancreatectomy was performed. The uniqueness of this case is that the spleen can be ectopic to the pancreas, what is even more unexpected is that the HAS undergone cystic change. When encountering a pancreatic mass, we need to think about the possibility of HAS. In conclusion, it is important to diagnose HAS with squamous cyst in the pancreatic tail presenting as other pancreatic masses. 2020 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Heterotopic accessory spleen (HAS); case report; contrast enhanced computed tomography (CE-CT); contrast enhanced ultrasound (CEUS); pancreas

Year:  2020        PMID: 32395551      PMCID: PMC7210170          DOI: 10.21037/atm.2020.03.79

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


Introduction

Heterotopic accessary spleen (HAS) is a separated ectopic splenic parenchyma due to an incomplete fusion of splenic masses during embryonic growth while arising from the midline to the left quadrant, which is often asymptomatic, however, its symptoms may be not-specific such as fatigue, abdominal pain, nausea. Pancreatic involvement is the most common presentation (1-3). However, HAS can appear in almost any other abdominal organ, including the stomach, kidney, greater omentum, mesenterium, and adnexal region et al. (4,5). If HAS in the pancreas can be confirmed by radiographic imaging, no treatment is necessary unless the lesion is symptomatic (6). If abdominal symptoms are actually related to pancreatic HAS, partial pancreatectomy is warranted. The pathologic examination revealed an encapsulated brownish mass, it was formed by red and white pulps. There are no previous reports of HAS with squamous epithelial cyst in pancreas. Herein, we describe a case of HAS in the tail of pancreas mimic other pancreatic lesion, which was identified postoperatively in a 49-year-old female.

Case presentation

A 49-year-old woman underwent ultrasonography at a periodic medical checkup on Jul 22, 2019, which revealed a mass in the tail of pancreas. Physical examination was normal, no obvious mass and anemic appearance. She had not significant past medical history. She had no surgery history except subtotal hysterectomy in 2012 because of multiple myomas in uterus. Her mother died of craniocerebral glioma in 2012, her father is suffering from hypertension and diabetes, and her sister is in good health. She denies history of similar disease, the family’s second-generation and third-generation infectious disease, genetic disease, psychosocial disease, familial disease and neoplastic disease. Laboratory data showed no abnormalities. The tumor marker such as CA 199, CA 125 and AFP values were within normal range. Chest X-ray was normal. Body mass index was 22.31 kg/m2. To further clarify the pancreatic mass, patient went to our hospital on Aug 5, 2019. Patient got reservation of triple phase helical contrast enhanced computed tomography (CE-CT) on Aug 8, 2019. Parameters were as follows: slice thickness 3 mm, tube voltage 120 kVp, tube current 400 mA. Iopamidol was used as a contrast medium and was administered at a dose of 2.5 mL/kg with a power injector. Precontrast, early arterial phase and late arterial phase were obtained. CE-CT revealed a hypo-intensity mass in the pancreas with heterogeneous wall enhancement in all phases, and the enhanced value of the mass was lower than that of the surrounding pancreatic parenchyma in all phases (). No retroperitoneal lymph nodes showed specific findings. Pancreatic mass, was considering solid pseudopapillary tumor with hemorrhage.
Figure 1

The CE-CT (A,B,C,D) and CE-MRI (E,F,G,H) images are demonstrating the enhanced pattern in all phases. A pancreatic mass was located at the tail. (A) Pre-contrast CT; (B) early arterial phase; (C) late arterial phase; (D) portal phase; (E) T2-weighted; (F) diffusion-weighted imaging; (G) arterial phase; (H) portal phase.

The CE-CT (A,B,C,D) and CE-MRI (E,F,G,H) images are demonstrating the enhanced pattern in all phases. A pancreatic mass was located at the tail. (A) Pre-contrast CT; (B) early arterial phase; (C) late arterial phase; (D) portal phase; (E) T2-weighted; (F) diffusion-weighted imaging; (G) arterial phase; (H) portal phase. Contrast enhanced ultrasound examination (CEUS) using SonoVue was performed with a 1–5 MHz convex transducer (Mindray Reasona 7, China) on Aug 9, 2019. Sonography revealed a tail of pancreatic mass 26.7×18.1 mm2 in diameter showing a homogeneously hypoechoic pattern. The occupation was well-circumscribed, and pathological blood flow was not detected in color Doppler (). The whole nodule was low-enhanced, ring-shaped high echoes can be seen in the periphery, and cord-like reinforcement can be seen in the nodule (). Solid pseudopapillary tumor was first considered. Contrast enhanced magnetic resonance imaging (CE-MRI) on Aug 10, 2019 revealed slightly low signal in diffusion-weighted and low signal in T2-weighted measuring 22.7×23.8 mm2 in diameter. The capsule wall and separation were visible enhancement. CE-MRI indicated benign cystic mass in the tail of the pancreas combing bleeding, mucinous cystadenoma was first considered.
Figure 2

The ultrasound images showing that a pancreatic mass was located at the tail. (A) B-mode; (B) color Doppler.

Figure 3

The CEUS imaging are demonstrating the different time (9 s/11 s/18 s/43 s) of blood perfusion. CEUS, contrast enhanced ultrasound.

The ultrasound images showing that a pancreatic mass was located at the tail. (A) B-mode; (B) color Doppler. The CEUS imaging are demonstrating the different time (9 s/11 s/18 s/43 s) of blood perfusion. CEUS, contrast enhanced ultrasound. Considering the risk of major bleeding according to image, outpatient admitted to hospital with “pancreatic mass” on Aug 12, 2019. Owing to daily healthy body and exclusion of surgical contraindications (no asthma etc.), laparotomy was performed under general anesthesia on Aug 16, 2019, during which inspection of the pancreas revealed an oval mass with a smooth surface after ultrasound knife opened gastrointestinal ligament. Carefully released upward along the middle colonic vein and superior mesenteric vein to open the posterior channel of the pancreas, and suspended the pancreas with a cloth tape. The upper end of the pancreas had obvious adhesion to the arteriovenous of the spleen. Carefully isolated the arteriovenous of the spleen, cut the pancreatic body on the right side of cyst with a cutting closure, and used electrocoagulate to stop pancreatic stump bleeding. The ultrasound knife separated the pancreas along the splenic arteriovenous, cut off the small branches between splenic arteriovenous and pancreas to prevent bleeding, and completely removed pancreatic body and tail within the lesion. 4-0 prolene interrupted sutured for hemostasis of pancreas. Intraoperative frozen section histologically composed of a squamous epithelial cyst with abundant sinusoids and lymphoid tissue in the periphery, finding which was almost consistent with HAS. The pancreatic mass was diagnosed as HAS with squamous epithelial cyst form (). Two flush drain tubes were indwelled in operation field. The operation was smooth, the anesthesia was stable during the operation, and the bleeding was about 300ml. The patient was sent to the resuscitation room after the operation. Cefmetazole was used to prevent infection, and symptomatic treatment was provided to protect the liver, stomach, analgesia, and enzyme inhibition. Postoperatively, the patient recovered well and was discharged on Aug 23, 2019, and kept a drainage tube for the pancreatic leakage. Discharged medicines were showing as follows: celecoxib capsule, compound lactobacillus acidophilus tablet, cefuroxime ester tablet, aspergillus oryzae trypsin tablet. Patient was advised to change gauze every three days and keep drainage tube unblocked after discharge, and sutures could be removed on Sep 6, 2019. She was followed up on Oct 6, 2019 with no complication which ultrasonography and lab test showed normal.
Figure 4

Photomicrographs of the pancreatic mass in the tail demonstrated HAS tissue combined with squamous epithelial cyst. (A) Hematoxylin and eosin stain (×40) shows that squamous epithelial cyst is enclosed by abundant splenic sinusoids, splenic cords and lymphoid tissues (arrow), pancreatic acini (asterisk) shows on the right side. (B) Sinusoids, scattered lymphoid follicles, and cystic wall of squamous epithelial cyst (asterisk) are visible in hematoxylin and eosin stain (×200).

Photomicrographs of the pancreatic mass in the tail demonstrated HAS tissue combined with squamous epithelial cyst. (A) Hematoxylin and eosin stain (×40) shows that squamous epithelial cyst is enclosed by abundant splenic sinusoids, splenic cords and lymphoid tissues (arrow), pancreatic acini (asterisk) shows on the right side. (B) Sinusoids, scattered lymphoid follicles, and cystic wall of squamous epithelial cyst (asterisk) are visible in hematoxylin and eosin stain (×200).

Discussion

During the spleen growth, it can develop anomalies such as complete agenesis, multiple spleens, HAS or persistent lobulation (7). HAS mostly appears in the hilum of the spleen followed by adjacent to the tail of the pancreas, left ovary, left testis, the greater omentum or mesentery of the small and large intestine (8,9). However, an atypical HAS with squamous epithelial cyst in the tail of pancreas has not been reported so far. The HAS is an incidental finding of no clinical significance in most patients (10). The preoperative accurate diagnosis of an HAS is difficult, especially when HAS with squamous epithelial cyst, as it can be mistaken for other mass-forming lesions (11). Although ultrasound, CE-CT, CE-MRI and other imaging modalities have certain diagnostic value, lack specificity (12,13). On the ultrasound, typical HAS presents mostly as a solitary round or oval mass with a well-defined boundary. On CEUS, it can visualize vascular hilum and enhanced intensity of HAS dynamically. On CT scan, HAS is depicted as a clear margin mass. On the CECT, it shows as a homogeneously enhanced density mass lesion similar to that of spleen. On MRI, the signal intensity of HAS is consistent with the main spleen in both T1-weighted and T2-weighted images (14). For evaluating a functional accessory, scintigraphy with Tc-99m phytate may a useful method. However, it is difficult to make a clinically preoperative diagnosis despite availability of multiple diagnostic tools. HAS always mimics tumor or lymphadenopathy in atypical location, not always typical, like this case HAS with squamous epithelial cyst. In this case, HAS confused with other pancreatic mass based on CECT or enhanced ultrasound. The contrast pattern mimicked other pancreatic mass such as solid papillary neoplasm, serous cystadenoma neoplasm, mucinous cystadenoma. In this case, no clinical symptom was apparent. However, it has been reported that some patient may present with abdominal pain, jaundice, malaise or other symptoms. Symptoms of HAS are atypical, requiring multiple imaging modalities for detection combined with clinical data. Routine laboratory tests are not usually helpful in the diagnosis of HAS, as these tests are nonspecific. The imaging features of HAS are variable, the typical feature is easy recognized. The diagnosis of HAS could be difficult due to the nonspecific nature of laboratory tests, asymptomatic, non-specific imaging feature (15). Macroscopically, HAS usually appears as a round or ovoid solid mass. Microscopically, HAS has a well-defined fibrotic capsule with hematopoietic cells, admixed with some certain small blood vessels which representing splenic sinusoids. In the present case, HAS is seen squamous cyst with surrounding abundant sinusoids and lymphocytes. A HAS with squamous cyst in the tail of pancreas has not been reported so far and extremely rare. HAS, should be considered in the differential diagnosis of pancreatic masses. After laparoscopic surgery, the patient presented well with no complication during 1-month follow-up. In this case, the pancreatic body and tail was resected together with lesion. The limitation is that it destroys a large amount of normal pancreatic tissue and increases the risk of pancreatic leakage. Knowing the pathological result, the surgical method is reversed, and the local excision of the lesion is more suitable. In conclusion, we reported a case of HAS with squamous cyst in the pancreatic tail presenting as other pancreatic masses. Although it is difficult to diagnose atypical HAS on multiple imaging modalities, it is important to note that HAS can present as other benign pancreatic masses, which are similar in appearance to HAS. The article’s supplementary files as
  1 in total

1.  Laparoscopic spleen-preserving distal pancreatectomy for epidermoid cyst in an intrapancreatic accessory spleen: A case report.

Authors:  Xiang Zheng; Bo Zhou; Jing-Qing Sun; Ming Jin; Sheng Yan
Journal:  Medicine (Baltimore)       Date:  2021-07-02       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.